SCHEMBL7124884

SCHEMBL7124884

Cc1ccnc(Oc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
LOX P28300 4/20 0.38
LOXL2 Q9Y4K0 4/20 0.38
EZH2 Q15910 1/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
PKM P14618 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DRD1 P21728 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MITF O75030 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
GRM5 P41594 1/20 0.37
MMP2 P08253 1/20 0.36
MMP7 P09237 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114437 0.89 LOX (0.40) LOXLOXL2RAB9AGRM5
SCHEMBL7125270 0.89 LOXL2 (0.38) POLBLOXLOXL2MMP2MMP7
SCHEMBL7123363 0.88 MMP13 (0.40) LOXLOXL2GRM5MMP2MMP7
SCHEMBL7116456 0.87 EGLN1 (0.39) EZH2GRM5MMP2MMP7MMP9
SCHEMBL7125166 0.87 KMT2A (0.40) LOXLOXL2SMN1; SMN2HTTGRM5
SCHEMBL7119303 0.85 SCN9A (0.44) NPC1RAB9A
SCHEMBL7122473 0.85 EPHX2 (0.39) LOXLOXL2NPC1RAB9AGRM5
SCHEMBL7123889 0.85 EZH2 (0.39) EZH2MMP2MMP7MMP9MMP13
SCHEMBL7122583 0.85 POLB (0.50) POLBNPC1RAB9ASMN1; SMN2MMP2
SCHEMBL7124962 0.82 POLB (0.37) POLBEZH2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 POLB 767/4885LOX 3030/4885LOXL2 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.